Follman Agency Burlington

Located in Burlington, IA, Follman Agency Burlington operates within the IA regulatory framework as a licensed addiction-treatment provider. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at Follman Agency Burlington

Level-of-care documentation: Follman Agency Burlington is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Follman Agency Burlington accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Specialty programming

The facility's documented specialty programming includes: Young adults, Seniors or older adults, Veterans. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission documentation for Follman Agency Burlington should include ASAM-framework level-of-care justification, plan-specific Verification of Benefits with network-contract confirmation, written MAT policy for opioid use disorder patients where applicable, and licensure/accreditation verification. If the clinical situation involves opioid use disorder, confirm explicitly whether Follman Agency Burlington offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.